TY  - CHAP
M1  - Book, Section
TI  - Cancer Genomics
A1  - Willis, Jason A.
A1  - Goldstein, Jennifer B.
A1  - Zhang, Zhijing
A1  - Futreal, Andy
A2  - Kantarjian, Hagop M.
A2  - Wolff, Robert A.
A2  - Rieber, Alyssa G.
PY  - 2022
T2  - The MD Anderson Manual of Medical Oncology, 4e
AB  - KEY  CONCEPTSThe  cancer  genomics  era  has  been  driven  by  rapid  technological  and  computational  advancements,  which  have  enabled  large-scale  multidimensional  analyses  of  rare  and  common  cancers  and  precursor  lesions.The  vast  majority  of  human  cancers  are  characterized  by  both  inter-  and  intratumor  molecular  heterogeneity,  which  adds  further  complexity  to  the  identification  of  robust  and  clinically  useful  biomarkers.Clonal  molecular  evolution  is  evident  throughout  multiple  stages  of  tumor  development  and  has  critical  implications  for  the  development  of  treatment  resistance  and  metastasis.Driven  by  the  development  of  cost-effective  and  robust  clinical  next-generation  sequencing  (NGS)  assays,  somatic  mutation  profiling  has  been  broadly  integrated  into  clinical  practice  for  patients  with  hematologic  malignancies  and  advanced  solid  tumors.  The  long-term  clinical  benefit  of  comprehensive  mutation  profiling  remains  to  be  defined.Despite  the  widespread  application  of  tumor  mutation  profiling  in  practice,  interpretation  of  the  results  and  therapeutic  decision  making  remains  challenging.  Institutional  resources  and/or  publicly  available  decision  tools  should  be  consulted  to  help  guide  providers  and  patients.Large-scale  studies  such  as  the  NCI-MATCH  study  and  the  MD  Anderson  IMPACT  study,  provide  a  critical  framework  for  matching  patients  with  biomarker-driven  clinical  trials,  which  is  a  hallmark  of  precision  oncology.  
SN  - 
PB  - McGraw Hill Education
CY  - New York, NY
Y2  - 2024/04/16
UR  - accessmedicine.mhmedical.com/content.aspx?aid=1190839035
ER  -